Stock CAPR CAPRICOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
5.17 USD -2.27% Intraday chart for Capricor Therapeutics, Inc. -1.34% +5.73%
Jun. 11 Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Jun. 11 Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
CI
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
CI
Oppenheimer Initiates Capricor Therapeutics at Outperform Rating
MT
Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024
Capricor: Q1 Earnings Snapshot
AQ
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M
MT
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
AQ
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting
CI
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
AQ
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
AQ
Transcript : Capricor Therapeutics, Inc. - Special Call
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. News Capricor Therapeutics, Inc.